Depression Research Study
Neurobehavioral Research, Inc. is evaluating a potential new treatment for patients with Major Depressive Disorder (MDD).
Fast Facts
Currently Depressed
Ages 18-75
In Stable Medical Condition
Compensation Provided
Conducted in Long Island, NY
Study Background
Scientists at Neurobehavioral Research, Inc. are evaluating the efficacy of a possible new treatment for Major Depressive Disorder.
Major Depressive Disorder (MDD) can impact everything from an individual’s mood, cognition, and behavior to their mortality. However, many patients struggle to find effective treatments because current methods are often limited by low efficacy or challenging side effects. As a result, there is significant demand for more diverse and effective treatment options for MDD.
In this study, we are evaluating BHV-7000 as a possible treatment for MDD. BHV-7000 is a medication which activates certain potassium channels that can counteract some of the effects of depression in the brain. We hope that by studying the effects of BHV-7000, we can demonstrate its potential to be an effective monotherapy treatment for MDD.
This study will require 7 in-person visits and last up to 12 weeks. Participants will be randomly assigned to take either BHV-7000 or a placebo, both of which will be provided at no cost.
Study Background
Scientists at Neurobehavioral Research, Inc. are evaluating the efficacy of a possible new treatment for Major Depressive Disorder.
Major Depressive Disorder (MDD) can impact everything from an individual’s mood, cognition, and behavior to their mortality. However, many patients struggle to find effective treatments because current methods are often limited by low efficacy or challenging side effects. As a result, there is significant demand for more diverse and effective treatment options for MDD.
In this study, we are evaluating BHV-7000 as a possible treatment for MDD. BHV-7000 is a medication which activates certain potassium channels that can counteract some of the effects of depression in the brain. We hope that by studying the effects of BHV-7000, we can demonstrate its potential to be an effective monotherapy treatment for MDD.
This study will require 7 in-person visits and last up to 12 weeks. Participants will be randomly assigned to take either BHV-7000 or a placebo, both of which will be provided at no cost.
Additional Information
This study aims to evaluate the efficacy and safety of BHV-7000 as a potential new treatment for Major Depressive Disorder.
You may qualify for this study if you meet the following criteria.
Inclusion Criteria:
- Currently depressed
- Ages 18-75
- In stable medical condition
- No history of bariatric surgery
Once enrolled, this study will last up to 12 weeks and involve 7 in-person visits:
- Screening Period (up to 4 weeks): Potential participants will first attend a screening visit and complete a screening phone call to determine eligibility to continue in the study. This will be followed by a baseline visit prior to entering the treatment phase of the study.
- Study Treatment Period (6 weeks): Participants will be randomly assigned to take either BHV-7000 or a placebo once per day during the 6-week treatment period. They will also complete 4 in-person visits during weeks 1, 2, 4, and 6. Participants who complete the treatment phase may have the option to participate in an Open-Level Extension study.
- Follow-up Period (2 weeks): Approximately two weeks after finishing the treatment phase, participants will complete an end-of-treatment safety visit.
Compensation is provided up to $150 per visit, for a total of up to $1050 across the 7 visits. Patients will also be compensated $100 for transportation.
There is no cost for you to participate in our research study.
